Skip to main content
Journal cover image

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder

Publication ,  Journal Article
Volavka, J; Czobor, P; Sheitman, B; Lindenmayer, JP; Citrome, L; McEvoy, JP; Cooper, TB; Chakos, M; Lieberman, JA
Published in: American Journal of Psychiatry
2002

Objective: The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder. Method: In a double-blind trial, 157 inpatients with a history of suboptimal treatment response were randomly assigned to treatment with clozapine, olanzapine, risperidone, or haloperidol for 14 weeks (an 8-week escalation and fixeddose period followed by a 6-week variable-dose period). Results: Clozapine, risperidone, and olanzapine (but not haloperidol) resulted in statistically significant improvements in total score on the Positive and Negative Syndrome Scale. Improvements seen in total and negative symptom scores with clozapine and olanzapine were superior to haloperidol. The atypical drugs, particularly olanzapine and clozapine, were associated with weight gain. Conclusions: The effects of atypical antipsychotics in this population were statistically significant but clinically modest. The overall pattern of results suggests that clozapine and olanzapine have similar general antipsychotic efficacy and that risperidone may be somewhat less effective. Clozapine was the most effective treatment for negative symptoms. However, the differences among treatments were small.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

American Journal of Psychiatry

DOI

ISSN

0002-953X

Publication Date

2002

Volume

159

Issue

2

Start / End Page

255 / 262

Related Subject Headings

  • Psychiatry
  • 5203 Clinical and health psychology
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J. P., Citrome, L., McEvoy, J. P., … Lieberman, J. A. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 159(2), 255–262. https://doi.org/10.1176/appi.ajp.159.2.255
Volavka, J., P. Czobor, B. Sheitman, J. P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman. “Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.” American Journal of Psychiatry 159, no. 2 (2002): 255–62. https://doi.org/10.1176/appi.ajp.159.2.255.
Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry. 2002;159(2):255–62.
Volavka, J., et al. “Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.” American Journal of Psychiatry, vol. 159, no. 2, 2002, pp. 255–62. Scival, doi:10.1176/appi.ajp.159.2.255.
Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry. 2002;159(2):255–262.
Journal cover image

Published In

American Journal of Psychiatry

DOI

ISSN

0002-953X

Publication Date

2002

Volume

159

Issue

2

Start / End Page

255 / 262

Related Subject Headings

  • Psychiatry
  • 5203 Clinical and health psychology
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences